Live Analyst Rating Changes 24961 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Trung Huynh
RBC

Trung Huynh

RBC Capital
Wall Street Analyst
★★★★☆
#607
on 13Foresight · ranked by our own returns
63%
Success Rate
+20.2%
Average Return
32 of 51 calls profitable · +29.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 63% of Trung Huynh's ratings turned a profit when each position was held for 1 year — averaging +20.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

28 Buy 13 Hold 4 Sell
Trung's Stock Coverage 34 ratings · 2026-08-16
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
LLY
Eli Lilly & Co
 Aug 05, 2026 BUY Strong Buy
-11.8% avg upside
48 analysts
$1500.00
27.11% Upside
 +1.0% ·
PFE
Pfizer
 Aug 04, 2026 HOLD Buy
+25.2% avg upside
45 analysts
$25.00
6.69% Downside
 +5.5% ·
MRK
Merck & Company
 Aug 04, 2026 BUY Strong Buy
-4.6% avg upside
43 analysts
$142.00
4.55% Upside
 +6.1% ·
BMY
Bristol-Myers Squibb
 Aug 04, 2026 HOLD Buy
-4.5% avg upside
42 analysts
$64.00
0.29% Upside
 -3.0% ·
ABBV
AbbVie
 Jul 31, 2026 BUY Strong Buy
-3.6% avg upside
46 analysts
$280.00
12.20% Upside
 -0.6% ·
JNJ
Johnson & Johnson
 Jul 21, 2026 BUY Strong Buy
-8.6% avg upside
39 analysts
$287.00
10.29% Upside
 +3.9% ·
REGN
Regeneron
 Nov 07, 2025 HOLD Strong Buy
-2.5% avg upside
58 analysts
$660.00
17.81% Downside
 +22.7% ·
JSPR
Jasper Therapeutics
 Aug 15, 2025 BUY Strong Buy
+3555.8% avg upside
18 analysts
$25.00
3064.12% Upside
 -74.6% ·
INSM
Insmed
 Aug 13, 2025 BUY Strong Buy
+42.2% avg upside
37 analysts
$140.00
13.08% Upside
 +2.8% ·
AMGN
Amgen
 Aug 06, 2025 HOLD Buy
-24.0% avg upside
57 analysts
$317.00
23.74% Downside
 +46.5% ·
ALXO
ALX Oncology Holdings
 May 21, 2025 BUY Strong Buy
+815.5% avg upside
11 analysts
$1.00
48.89% Downside
 +385.4% ·
CLDX
Celldex
 May 09, 2025 BUY Strong Buy
-2.5% avg upside
28 analysts
$38.00
9.42% Downside
 +85.3% ·
CABA
Cabaletta Bio
 Apr 01, 2025 BUY Strong Buy
+406.1% avg upside
16 analysts
$7.00
154.60% Upside
 +129.1% ·
KYTX
Kyverna Therapeutics, Inc.
 Mar 29, 2025 BUY Strong Buy
+234.6% avg upside
7 analysts
$12.00
46.85% Upside
 +304.2% ·
ABOS
Acumen Pharmaceuticals
 Mar 28, 2025 BUY Strong Buy
+203.8% avg upside
10 analysts
$4.00
49.82% Upside
 +89.9% ·
ES:GRF
Grifols
 Aug 24, 2023 HOLD Buy
+49.7% avg upside
12 analysts
$13.50
37.01% Upside
 -23.7% ·
CH:LONN
Lonza Group Ltd
 Dec 07, 2022 BUY Strong Buy
+15.0% avg upside
21 analysts
$580.00
3.05% Upside
 -27.5% ·
GB:0MGB
Genmab A/S
 Aug 11, 2022 HOLD Buy
-2.2% avg upside
23 analysts
$2600.00
28.28% Upside
 -2.5% ·
CH:ROP
Roche Holding AG
 Jul 24, 2022 HOLD Buy
-5.7% avg upside
23 analysts
$350.00
1.36% Downside
 -13.6% ·
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
 May 11, 2022 SELL Hold
-8.1% avg upside
7 analysts
$40.00
23.86% Downside
 -13.6% ·
ES:ALM
Almirall
 May 10, 2022 HOLD Buy
+26.7% avg upside
5 analysts
$12.00
14.52% Upside
 -15.0% ·
FR:IPN
Ipsen
 Apr 13, 2022 HOLD Hold
-20.4% avg upside
17 analysts
$105.00
32.74% Downside
 -5.4% ·
GB:0QIU
Novo Nordisk
 Apr 01, 2022 HOLD Hold
+39.0% avg upside
29 analysts
$670.00
127.40% Upside
 · ·
DE:BAYN
Bayer
 Dec 13, 2021 HOLD Strong Buy
+9.7% avg upside
30 analysts
$57.00
19.04% Upside
 +15.8% ·
GB:AZN
AstraZeneca
 Nov 15, 2021 BUY Strong Buy
+26.9% avg upside
26 analysts
$9000.00
21.43% Downside
 +20.5% ·
GRFS
Grifols SA
 Aug 04, 2021 BUY Buy
+226.0% avg upside
12 analysts
$31.22
301.24% Upside
 -40.4% ·
GB:GSK
GlaxoSmithKline
 Jun 22, 2021 SELL Hold
+6.0% avg upside
25 analysts
$1400.00
23.01% Downside
 -22.1% ·
DE:MRK
Merck KGaA
 May 13, 2021 BUY Buy
+0.9% avg upside
33 analysts
$165.00
21.06% Upside
 +15.2% ·
FR:SAN
Sanofi
 Apr 29, 2021 BUY Strong Buy
+28.9% avg upside
30 analysts
$96.00
27.18% Upside
 +20.4% ·
CH:NOVN
Novartis AG
 Apr 28, 2021 HOLD Buy
-9.4% avg upside
32 analysts
$90.00
26.40% Downside
 +15.4% ·
GB:0M2O
Orion Corporation
 Jan 20, 2021 SELL Strong Sell
-58.9% avg upside
3 analysts
$35.00
54.87% Downside
 +2.8% ·
NVO
Novo Nordisk
 Oct 12, 2020 BUY Buy
+152.7% avg upside
26 analysts
$72.66
58.33% Upside
 +35.2% ·
GB:0NZT
UCB SA
 Jul 28, 2020 HOLD Buy
+3.1% avg upside
19 analysts
$83.00
61.47% Downside
 -16.3% ·
GMAB
Genmab
 Jun 25, 2020 HOLD Strong Buy
+11.3% avg upside
27 analysts
$3.46
89.12% Downside
 +26.4% ·
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Trung Huynh — Frequently Asked Questions
How accurate are Trung Huynh's stock ratings?
Based on the calls 13Foresight could measure, about 63% of Trung's ratings were profitable over a one-year hold, with an average return of +20.2% per rating, or +12.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Trung ranked on 13Foresight?
Trung Huynh is currently ranked #607 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Trung cover?
Trung most recently has ratings on LLY, PFE, MRK, BMY, ABBV, JNJ, REGN, JSPR, INSM, AMGN, ALXO, CLDX and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.